Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages E270-E275

  Klink, Daniel ^a   Caris, Martine ^a   Heijboer, Annemieke ^a   Van Trotsenburg, Michael ^a   Rotteveel, Joost ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; TESTOSTERONE; TRIPTORELIN; GONADORELIN;

ADULT; ADULTHOOD; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; CASE REPORT; DRUG DOSE INCREASE; FEMALE; FEMALE TO MALE TRANSGENDER; GENDER DYSPHORIA; HORMONAL THERAPY; HUMAN; LONGITUDINAL STUDY; MALE; MALE TO FEMALE TRANSGENDER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEX REASSIGNMENT; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; BODY HEIGHT; DRUG EFFECTS; LUMBAR VERTEBRA; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOGRAPHY; SEXUAL MATURATION; TRANSSEXUALISM; TREATMENT OUTCOME;

ADOLESCENT; BODY HEIGHT; BONE DENSITY; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUMBAR VERTEBRAE; MALE; SEXUAL MATURATION; TRANSSEXUALISM; TREATMENT OUTCOME; TRIPTORELIN PAMOATE; YOUNG ADULT;

EID: 84927566048     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2439     Document Type: Article

References (22)

1. Delemarre-van de Waal H, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinology. 2006; 155(Suppl. 1): S131-S137.
2. de Vries AL, Steensma TD, Doreleijers TA, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: A prospective follow-up study. J Sex Med. 2011; 8(8): 2276-2283.
3. Alessandri SB, Pereira Fde A, Villela RA, et al. Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist. Clinics (Sao Paulo). 2012; 67(6): 591-596.
4. Antoniazzi F, Zamboni G, Bertoldo F, et al. Bone massatfinal height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab. 2003; 88(3): 1096-1101.
5. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999; 84(12): 4583-4590.
6. Leslie WD, Majumdar SR. Treatment implications for men when switching from male to female bone mineral density reference data: TheManitobaBone Density Program. JClin Densitom.2013;16(4): 537-542.
7. Ward KA, Ashby RL, Roberts SA, Adams JE, Zulf Mughal M. UK reference data for the Hologic QDR Discovery dual-energy x ray absorptiometry scanner in healthy children and young adults aged 6-17 years. Arch Dis Child. 2007; 92(1): 53-59.
8. Boot AM, de Ridder MA, van der Sluis IM, van Slobbe I, Krenning EP, Keizer-Schrama SM. Peak bone mineral density, lean body mass and fractures. Bone. 2010; 46(2): 336-341.
9. Van Coeverden SC, De Ridder CM, Roos JC, et al. Pubertal maturation characteristics and the rate of bone mass development longitudinally toward menarche. J Bone Miner Res. 2001; 16(4): 774-781.
10. van Coeverden SC, Netelenbos JC, ve Ridder CM, et al. Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf). 2002; 57(1): 107-116.
11. Van Caenegem E, Wierckx K, Taes Y, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab. 2012; 97(7): 2503-2511.
12. Lapauw B, Taes Y, Simoens S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008; 43(6): 1016-1021.
13. Wang Q, Alén M, Nicholson PHF, et al. Differential effects of sex hormones on peri- and endocortical bone surfaces in pubertal girls. J Clin Endocrinol Metab. 2006; 91(1): 277-282.
14. Lips P, Asscheman H, Uitewaal P, Netelenbos JC, Gooren L. The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. J Bone Miner Res. 1989; 4(5): 657-662.
15. Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone. 2013; 54(1): 92-97.
16. Haraldsen IR, Haug E, Falch J, Egeland T, Opjordsmoen S. Crosssex pattern of bone mineral density in early onset gender identity disorder. Horm Behav. 2007; 52(3): 334-343.
17. Mueller A, Dittrich R, Binder H, et al. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol. 2005; 153(1): 107-113.
18. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94(9): 3132-3154.
19. van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J. Longterm follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf). 1998; 48(3): 347-354.
20. Mughal MZ, Khadilkar AV. The accrual of bone mass during childhood and puberty. Curr Opin Endocrinol Diabetes Obes. 2011; 18(1): 28-32.
21. Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics. 2012; 129(3): 418-425.
22. Hewitt JK, Paul C, Kasiannan P, Grover SR, Newman LK, Warne GL. Hormone treatment of gender identity disorder in a cohort of children and adolescents. Med J Aust. 2012; 196(9): 578-581.